Improving emergency care for cancer patients experiencing immune-related side effects
Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi)
This study is working to help emergency room doctors quickly spot and treat serious side effects that cancer patients might have from their immune therapy, so they can get the right care when they need it most.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11000331 on NIH RePORTER |
What this research studies
This research focuses on enhancing the emergency care provided to cancer patients who experience immune-related adverse events (irAEs) due to immune checkpoint inhibitors. It aims to develop a tool that helps emergency department clinicians quickly recognize these events and make informed decisions about whether to admit, observe, or discharge patients. By collaborating across multiple cancer centers, the study will gather extensive clinical, biological, and laboratory data to improve patient outcomes in emergency settings. The goal is to ensure timely and appropriate care for patients facing potentially severe complications from their cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving immune checkpoint inhibitors who may present with immune-related adverse events.
Not a fit: Patients not undergoing treatment with immune checkpoint inhibitors or those without immune-related adverse events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved emergency care protocols that significantly reduce morbidity and mortality for cancer patients experiencing irAEs.
How similar studies have performed: Previous research has shown success in improving emergency care protocols for cancer patients, indicating that this approach has the potential for meaningful advancements.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Reyes-Gibby, Cielito C — University of Tx Md Anderson Can Ctr
- Study coordinator: Reyes-Gibby, Cielito C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.